Anatoly Martynyuk, MD
My current research predominantly focuses on the contribution of
abnormal glutamatergic activity to the etiology of CNS disorders, such as
stroke, epileptic seizures, and schizophrenia, and on drug development for
their treatments.
We have been studying the concept that antiglutamatergic agents with
multisite actions and moderate potency have the potential to overcome the
limitations of previously tested highly selective and potent
antiglutamatergic agents, by producing efficacious neuroprotection and still
enabling a level of balanced glutamate receptor activity required for
physiological brain functions and thus avoiding side effects.
The most recently initiated project in our laboratory aims at validating the
hypothesis that GABAA receptor enhancing general anesthetics cause cortical
excitation and delayed impairment of cognition in neonates and infants.
1. Martynyuk AE, Ucar DA, Yang DD, Norman WM, Carney PR, Dennis DM, Laipis
PJ. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine
levels.
Epilepsia. 2007 Jun;48(6):1143-50.
2. Martynyuk AE, Seubert CN, Yarotskyy V, Glushakov AV, Gravenstein N,
Sumners C, Dennis DM. Halogenated derivatives of aromatic amino acids
exhibit balanced antiglutamatergic actions: potential applications for the
treatment of neurological and neuropsychiatric disorders.
Recent Patents CNS Drug Discov. 2006 Nov;1(3):261-70. Review.
3. Yarotskyy V, Glushakov AV, Sumners C, Gravenstein N, Dennis DM, Seubert
CN, Martynyuk AE. Differential modulation of glutamatergic transmission by
3,5-dibromo-L-phenylalanine.
Mol Pharmacol. 2005 May;67(5):1648-54.
4. Glushakov AV, Glushakova O, Varshney M, Bajpai LK, Sumners C, Laipis PJ,
Embury JE, Baker SP, Otero DH, Dennis DM, Seubert CN, Martynyuk AE.
Long-term changes in glutamatergic synaptic transmission in phenylketonuria.
Brain. 2005 Feb;128(Pt 2):300-7.
5. Kagiyama T, Glushakov AV, Sumners C, Roose B, Dennis DM, Phillips MI,
Ozcan MS, Seubert CN, Martynyuk AE. Neuroprotective action of halogenated
derivatives of L-phenylalanine.
Stroke. 2004 May;35(5):1192-6.
